Skip to main content
. 2017 May 2;8(28):46145–46162. doi: 10.18632/oncotarget.17574

Figure 5. The role of CxCa-Sig in clinical outcomes of cervical cancer patient.

Figure 5

The expression of CxCa-Sig in cervical cancer patients containing responders and non-responders to neoadjuvant chemotherapy using nedaplatin and irinotecan before the surgery (A), and chemoradiotherapy using cisplatin with or without surgery (B) was analyzed by GSEA.